{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-163498","form_type":"8-K","ticker":"URGN","cik":"0001668243","company_name":"UroGen Pharma Ltd.","filed_at":"2024-06-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.503953+00:00","generated_at":"2026-06-01T03:55:04.040691+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"UroGen Pharma prices $107.5M public offering of 5M shares at $17.50, plus pre-funded warrants","bullets":["Offering: 5,000,000 ordinary shares at $17.50/share plus 1,142,857 pre-funded warrants at $17.499 each.","Gross proceeds expected to be approximately $107.5 million before underwriting discounts and expenses.","Underwriters granted a 30-day option to purchase up to an additional 921,428 ordinary shares.","Closing expected on June 20, 2024, subject to customary conditions.","TD Cowen and Guggenheim Securities are joint book-running managers; Oppenheimer & Co. is lead manager."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-163498","json":"https://secwatch.observer/filing/0001193125-24-163498.json","markdown":"https://secwatch.observer/filing/0001193125-24-163498.md","text":"https://secwatch.observer/filing/0001193125-24-163498.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1668243/000119312524163498/0001193125-24-163498-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1668243/000119312524163498/d854991d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T03:55:04.040691+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}